Navigation Links
Baxa Corporation Recognized for Pharmacy Automation Leadership and Business Growth
Date:8/25/2010

ENGLEWOOD, Colo., Aug. 25 /PRNewswire/ -- Baxa Corporation today announced its rank of 3,494 on the Inc. 5000 list of the fastest-growing private businesses in the United States. This year marks the fourth consecutive year that Baxa, a leading provider of medical devices and systems that automate pharmacy operations, has been listed on the prestigious Inc. 5000 list.

(Logo:  http://photos.prnewswire.com/prnh/20100817/INC5000LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100817/INC5000LOGO)

"Our growth is due in large part to our continued focus on developing pharmacy technology and automation devices that provide Directors of the Pharmacy with a high degree of safety, speed and certainty in their IV dose preparation," said Greg Baldwin, Baxa Chairman and CEO.  "This focus has led to our continued market penetration and reputation for quality, which have earned Baxa multiple recent accolades, including our fourth year on the Inc. 5000 list."

In addition to the Inc. 5000 listing, Baxa Corporation's market leadership was recently recognized by Pharmacy Purchasing & Products (PP&P), the premier magazine for health system pharmacists, in its August 2010 "Pharmacy Automation Guide."  The market study surveyed more than 400 health system pharmacy directors, with results that show:

  • Baxa holds a 75% share of compounding robots in use with the IntelliFill® i.v. System.
  • Baxa leads the marketplace with a 68% share of automated compounding devices with the ExactaMix™ Automated Compounders.
  • Baxa holds a 50% share of IV workflow management with the DoseEdge® Pharmacy Workflow Manager, including a 64% share of vendor consideration.

  • These findings are further supported by the more than 3,000 hospitals worldwide that use Baxa products every day to produce more than 450,000 safe medication doses.  

    Looking at the market as a whole, recent comments from PP&P publisher R. Mitchell Halvorsen, in the article, "Signs of an Automation Rebound in 2010!," predict "cautious optimism regarding the state of affairs in health-care capitalization, but also a clear indication that the importance of automation cannot be overlooked."  

    To view the entire August 2010 edition of Pharmacy Purchasing & Products click: http://pppmag.com/digitalmag/Main.php?MagID=2&MagNo=21.

    Driven by strong business growth, Baxa is in the process of doubling its production cleanroom, assembly and warehouse space to ensure on-time shipment of Baxa products to customers around the world. To make room for expanded production, the company recently opened a new corporate headquarters, located at 9540 S Maroon Circle, Englewood, Colorado, encompassing 64,000 square feet of office and laboratory space.

    To learn more about Baxa and its line of leading IV automation products, please visit: http://www.baxa.com/PharmacyProducts. To request additional information visit: www.baxa.com, call 1-800-567-BAXA, or email info@baxa.com.

    About Baxa CorporationBaxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications.  Key products include the Abacus® Order Entry and Calculation Software, the DoseEdge Pharmacy Workflow Manager (formerly IntelliFlow™), ExactaMed® Oral Dispensers, ExactaMix™ Automated Compounding Devices, MicroFuse® Syringe Infusers, Repeater Pharmacy Pumps, the PadLock®  Set Saver and the RapidFill Automated Syringe Filler; used worldwide in hospitals and healthcare facilities.  Its subsidiary FHT, Inc. produces the IntelliFill i.v. automation.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.

    Further information is available at www.baxa.com.

    About Inc.comInc.com, the Daily Resource for Entrepreneurs, delivers advice, tools, breaking news, and rich multi-media to help business owners and CEOs start, run, and grow their businesses more successfully.  Information and advice covering virtually every business and management task, including marketing, sales, finding capital, managing people can be found at http://www.inc.com.Contact:Marian Robinson, Vice President, MarketingBaxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157Email:  marian.robinson@baxa.comPerrin McCormick or Brandie GerrishHart-Boillot: 781-893-0053Email: baxa@hartboillot.com
    '/>"/>

    SOURCE Baxa Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    2. CEL-SCI Corporation Releases Letter to Shareholders
    3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
    4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
    5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
    6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
    7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
    8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
    9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
    10. Immunosyn Corporation Releases SF-1019 Study Results
    11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2016)... ALBANY, New York , May 4, 2016 /PRNewswire/ ... published by Transparency Market Research entitled "Brain Computer Interface Market ... Forecast 2016 - 2024," the  global brain computer interface (BCI) ... bn by 2024. The market is estimated to expand ... period from 2016 to 2024. A BCI ...
    (Date:5/4/2016)... D.C. , May 4, 2016 ... member companies concluded a series of free workshops ... in global requirements for Good Distribution ... of quality assurance which ensures that products are consistently stored, ... the marketing authorization (MA) or product specification. Only a ...
    (Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
    Breaking Medicine Technology:
    (Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... on the eve of National Nurses Week (May 6-12). Currently, HireNurses is ... With their enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically ...
    (Date:5/5/2016)... ... May 05, 2016 , ... VisualDx ... Android devices. VisualDx is the first point of care diagnostic support system ... medicine. The system speeds diagnosis, therapy decisions and patient education for emergency ...
    (Date:5/5/2016)... ... 05, 2016 , ... ACLS Certification Institute, a leading provider ... program, giving participants incentive for spreading the word about the Institute’s certification and ... professionals share resources with their friends and colleagues,” said Vonda Andrews, ACLS Certification ...
    (Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD ... Louis, Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was titled ... the conference about her unique specialization in treating Lipedema. Dr. Byrd is considered one ...
    (Date:5/5/2016)... ... ... Is the part in your hair widening? Are you finding more hairs ... good opportunity to raise awareness about a common condition among women: hair loss. , ... experience hair loss or ‘thinning’ by the time they reach menopause, but many remain ...
    Breaking Medicine News(10 mins):